Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a…

By A. Kavanaugh, I. McInnes, P. Mease, G. Krueger, D. Gladman, J. Gómez-Reino, K. Papp, J. Zrubek, S. Mudivarthy, M. Mack and 2 more. Arthritis & Rheumatism, 2009

614 citations recorded by the source corpus.

Subfields: Immunology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/89f40679de37513d7ce9ee1523f031697b308e16